Journal of Clinical Endocrinology & Metabolism, Vol 77, 658-663, Copyright © 1993 by Endocrine Society

ARTICLES

Dual mechanism of perturbation of thyrotropin-mediated activation of thyroid cells by antibodies to the thyrotropin receptor (TSHR) and TSHR- derived peptides

RK Desai, JS Dallas, MK Gupta, GS Seetharamaiah, JL Fan, K Tahara, LD Kohn and BS Prabhakar
Department of Microbiology, University of Texas Medical Branch, Galveston, 77555.

To further define the epitopes with which anti-TSH receptor (anti-TSHR) antibodies react and mediate their biological effects, we used antibodies against the extracellular domain of TSHR (ETSHR) protein and nine peptides derived from the ETSHR. Peptides were chosen based on their predicted immunogenicity as well as their uniqueness to the TSHR. Antipeptide antibodies showed varying degrees of reactivity against ETSHR, with antipeptide-2-(352-366) and -3A-(357-372) showing relatively stronger reactivity with the receptor. Antibodies were tested for their ability to stimulate thyroid cells and were found to be ineffective in causing both cAMP release and iodide uptake. However, anti-3A and anti-ETSHR showed blocking TSHR antibody (TSHRAb) activities of 76.9% and 79.7%, respectively, which were significantly different (P < 0.005) compared to that of preimmune serum. Anti-2 and - 91 (AA 32-46) also showed blocking TSHRAb activities of 37.5% and 35.6%, respectively (P < 0.05). Antisera were also tested for their ability to block TSH binding to thyroid membranes in a RRA. Anti-ETSHR, but not any of the antipeptide antibodies, displayed TSH binding inhibitory immunoglobulin activity. These findings suggest that there might be different mechanisms that mediate blocking TSHR antibody activity. One mechanism involves the inhibition of TSH binding to the receptor, and the other probably involves a step subsequent to TSH binding.

This article has been cited by other articles:

				S. P. Singh, D. McDonald, T. J. Hope, and B. S. Prabhakar Upon Thyrotropin Binding the Thyrotropin Receptor Is Internalized and Localized to Endosome Endocrinology, February 1, 2004; 145(2): 1003 - 1010. [Abstract] [Full Text] [PDF]

				B. Rapoport, G. D. Chazenbalk, J. C. Jaume, and S. M. McLachlan The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies Endocr. Rev., December 1, 1998; 19(6): 673 - 716. [Abstract] [Full Text]

				S. Kikuoka, N. Shimojo, K.-I. Yamaguchi, Y. Watanabe, A. Hoshioka, A. Hirai, Y. Saito, K. Tahara, L. D. Kohn, N. Maruyama, et al. The Formation of Thyrotropin Receptor (TSHR) Antibodies in a Graves' Animal Model Requires the N-Terminal Segment of the TSHR Extracellular Domain Endocrinology, April 1, 1998; 139(4): 1891 - 1898. [Abstract] [Full Text] [PDF]

				S. A. Patibandla, J. S. Dallas, G. S. Seetharamaiah, K. Tahara, L. D. Kohn, and B. S. Prabhakar Flow Cytometric Analyses of Antibody Binding to Chinese Hamster Ovary Cells Expressing Human Thyrotropin Receptor J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1885 - 1893. [Abstract] [Full Text] [PDF]

				W. B. Kim, H. K. Chung, H. K. Lee, L. D. Kohn, K. Tahara, and B. Y. Cho Changes in Epitopes for Thyroid-Stimulating Antibodies in Graves' Disease Sera During Treatment of Hyperthyroidism: Therapeutic Implications J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1953 - 1959. [Abstract] [Full Text] [PDF]